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Backgroud: The prognostic value of CRP and the beneficial effects of chronic statin therapy in patients (pts) with Acute Coronary Syndrome is 
well established. Objective of this study was to define in a large population of pts undergoing planned percutaneous coronary intervention (PCI) the 
prognostic value of chronic statin therapy in relation with baseline values of CRP.
Method: 1000 stable pts were enrolled. Follow-up (30+/-6 months) was completed in 839 pts. CRP was evaluated on baseline in all pts, values 
≥4.0 were considered abnormal. The events taken into consideration during FU were: 1. cardiac death; 2. total mortality; 3. hospitalization for 
myocardial infarction (MI) or unstable angina (UA). MACE were defined death for cardiac cause, non fatal MI and UA.
Results: CRP ≥4.0 was documented in 31% of our population; in these pts the incidence of total mortality, cardiac death, MI and MACE were 
significantly higher than in those with CRP<4.0 (total mortality: 6.5% vs 1.9, p=0.0005; cardiac death:4.6% vs 1.1%, p=0.002; MI: 5% vs 1.7%, 
p=0.006; MACE: 10.3% vs 4%, p=0.0004). Then, the pts were divided into 4 groups according to CRP values and to the presence/absence of chronic 
statin therapy: G1 included 95 pts with CRP<4.0 and not on statin therapy during FU; G2 483 pts with CRP<4.0 and on statins; G3 67 pts with ≥4.0 
not on statins and G4 194 pts with CRP ≥4.0 and on statins. The incidences of events in each group were the following:
Total mortality: 4.2% in G1, 1.24% in G2, 9% in G3, 5.7% in G4, p=0.0005
Cardiac Death: 2.1% inG1, 0.8% in G2, 7.5% in G3, 3.6% in G4, p=0.001
MACE: 7.4% in G1, 3.3% in G2, 17% in G3, 8.2% in G4, p=0.00008
MI: 3% in G1, 1.2% in G2, 4.5% in G3, 5.2% in G4, p=0.02
Pts with CRP ≥4.0 and not on statins showed the higher incidence of cardiac death and MACE. In pts with elevated CRP the addition of statins 
reduced the risk of cardiac death and MACE to percentages similar to those of pts with CRP<4.0 and not on statins.
Conclusion: Our data documented that baseline CRP values have an important prognostic role in stable pts undergoing PCI. Statin therapy 
significantly affects the incidence of cardiac events in all pts but particularly in those with elevated CRP in whom chronic statins abolishes the 
additive risk related to CRP
